Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the response of patupilone plus prednisone compared
to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic
hormone refractory prostate cancer. Additionally, this study will assess the response on
measureable disease and the effects on patient-reported outcomes.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Docetaxel Epothilone B Epothilones Hormones Prednisone